In this regard, one such vaccine, mRNA-5671/V941, targets four KRAS mutations, including G12D-, G12V-, G13D-, and G12C-, is tested in combination with pembrolizumab in stage I experimental trial for patients with KRAS-mutant advanced colorectal cancer under the clinical reference ID of NCT03948763 (240–242). Here, KRAS is linked to colorectal cancer.